Cooperative Agreement U01AG089242
Award Date
8/15/24
Completion Date
7/31/28
Dollars Obligated
$1.1M
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Cooperative Agreement
Place of Performance
San Antonio, TX 78229, USA
Similar Awards
The University of Texas Southwestern Medical Center received a $618,401 Cooperative Agreement award from the National Institute on Aging (CFDA 93.866 - Aging Research) to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of mTOR inhibitors, such as sirolimus and everolimus, in older adults. The primary goal is to precisely estimate fundamental PK/PD parameters of these drugs in older adults without confounding illnesses. This research will validate measurement techniques, quantify...
This $640,068 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to study the impact of the drug everolimus on chronic inflammation in aging through an ancillary study (IMTOR) to the NIA-funded EVERLAST trial. The IMTOR study will focus on analyzing the effects of everolimus on immune cell function, particularly CD4+ T cells, to determine how the drug can reduce age-related inflammation and improve healthspan. The project will involve...
The National Institute on Aging (NIA) awarded a Project Grant (CFDA 93.866, Aging Research) to Texas A&M AgriLife Research to conduct the "Test of Rapamycin in Aging Dogs (TRIAD)" clinical trial. The $2,015,762 award, effective December 1, 2024 through November 30, 2029, will support a randomized, double-blind, placebo-controlled veterinary trial to determine if weekly rapamycin treatment can increase lifespan and healthspan in 580 companion dogs. The study will also assess the...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,414,024 to The University of Texas Health Science Center at San Antonio to study the role of paracrine growth factor signaling in thymus function and age-associated dysfunction. The research aims to independently manipulate FGF21, mTOR, and autophagy pathways to understand their regulatory relationships and effects on cortical thymic epithelial cell (cTEC) size, morphology, and overall thymus...
This is a Cooperative Agreement award from the National Institute on Aging (NIA), under the federal Aging Research grant program (CFDA 93.866), totaling $1,001,704 with a project period from August 2024 to July 2029. The award is to The Trustees of the University of Pennsylvania to conduct research aimed at developing and standardizing methods for analyzing nicotinamide adenine dinucleotide (NAD) and its metabolites in blood, serum, urine, and tissues. The key objectives are to: 1) establish...
This $1,020,661 Cooperative Agreement award, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to develop and validate standardized methods for measuring NAD+ and related metabolites in human samples. The key products and services to be delivered include: Optimizing and validating sample collection and storage protocols to preserve the integrity of NAD+, NADH, NADP, and NADPH metabolites. Finalizing validation of an advanced liquid chromatography-tandem mass...
This Project Grant award of $674,227 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a study at New York University to examine the impact of the 340B Drug Pricing Program on medication utilization, health outcomes, and disparities in the Medicare population. The research aims to evaluate how the growth of the 340B program has affected Medicare Part D medication volumes, characteristics, guideline-concordant use, adherence, and health outcomes, with a focus on...
This federal Project Grant award of $507,325 from the National Institute on Aging (CFDA 93.866 - Aging Research) to the University of Texas Health Science Center at Houston (UTHealth) aims to investigate the role of ROR (retinoid acid receptor-related orphan receptor) nuclear receptors in regulating mitochondrial function and skeletal muscle aging. The key objectives are to: 1) comprehensively examine age- and circadian time-dependent changes in mitochondrial activity and homeostasis in skeletal...
This $644,864 Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports preclinical studies by Ridgeline Therapeutics LLC, a Houston-based biotech company, to evaluate the efficacy of their lead compound RT-002 in preventing and reversing disuse-induced muscle atrophy in aging rat models. Specifically, the project aims to determine if RT-002 treatment can mitigate the loss of muscle mass and strength during muscle disuse, as well as improve the rate...
This federal Project Grant award of $2,496,057.49 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the role of hepatic glucagon receptor signaling in healthspan and aging. The research project at the University of Arizona will use genetic and pharmacological approaches to manipulate glucagon receptor signaling and study its impact on normal aging, obesity-accelerated aging, and calorie restriction-induced longevity extension. The project builds on prior...